News headlines about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 47.1099451353192 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of research analysts have recently commented on the stock. Goldman Sachs Group initiated coverage on shares of T2 Biosystems in a research report on Monday, January 29th. They set a “neutral” rating and a $5.20 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of T2 Biosystems in a research note on Thursday, January 25th. Zacks Investment Research cut shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $6.00 price objective on shares of T2 Biosystems in a research note on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $6.37.
Shares of T2 Biosystems (TTOO) opened at $4.67 on Monday. T2 Biosystems has a 52 week low of $2.50 and a 52 week high of $6.99. The company has a debt-to-equity ratio of 2.25, a quick ratio of 5.28 and a current ratio of 5.40. The company has a market cap of $167.30, a P/E ratio of -2.46 and a beta of 1.71.
WARNING: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-t2-biosystems-ttoo-share-price.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.